Carriers of COVID-19, cerebral microbleeds, may be predisposed to severe COVID-19, cerebral microbleeds, according to a common risk factor for Alzheimer’s disease.

Carriers of a common risk gene for Alzheimer’s disease may be predisposed to severe COVID-19, cerebral microbleeds.

According to a study conducted at the University of Helsinki and Helsinki University Hospital, the APOE4 allele may also increase cerebral microbleeds and be associated with mental fatigue caused by prolonged COVID.

APOE4 is a genetic variant that predisposes carriers to disease. About a third of Finns wear it.

Researchers have found an association between APOE4 and COVID-19 in terms of increased susceptibility to infection and COVID-19 mortality worldwide.

The association between the APOE4 allele and the severity of COVID-19 in the Finnish population has been investigated by a research group at the University of Helsinki and Helsinki University Hospital (HUS).

The interdisciplinary team also examined microscopic cerebral changes in the carcasses of COVID-19 patients, as well as the association between APOE4 and symptoms of mental fatigue six months after the onset of the disease.

The research was published in the journal Acta Neuropathologica Communications.

“In the Finnish population, the common 4-allele of the APOE gene appears to be associated with a higher risk of severe COVID-19.”

According to Liisa Myllykangas, a consultant neuropathologist at the University of Helsinki and HYY, “the importance of APOE4 in the Finnish population is significant, which may be due to its genetic homogeneity.”

The risk of developing a form of COVID-19 that requires intensive treatment has more than doubled in carriers of the APOE4 allele, according to the results.

In addition, carriers of this allele in the study had more microscopic bleeding in the brain due to severe COVID-19 than non-carriers.

APOE4 can also affect the severity of certain long-term symptoms, according to chief physician, intensivist Johanna Hästbacka, especially in the case of COVID-19, which requires hospitalization.

“One such symptom identified in the study was mental fatigue, which was defined as difficulty concentrating and concentrating,” says Hästbacka.

Myllykangas points out that the number of COVID-19 patients in the data sets examined was relatively small, so the results must be considered as indicative at present.

“These phenomena need to be investigated in larger datasets to confirm our results,” she says.

The study did not address the association between COVID-19 and the onset of memory disorders in APOE4 carriers, which is an important issue.

“Long-term follow-up studies of COVID-19 patients as well as basic research focused on the combined effects of APOE4 and systemic … are needed to answer this question.”

Summary of the latest news from Brinkwire.

Leave a Comment